FDA Accepts Samaritans Cushings SP-6300 IND and Clears Phase II Study
Summary
Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushings syndrome SP-6300s efficacy in patients experiencing Hypercortisolism.It helps maintain blood pressure and cardiovascular function, reduces the immune systems inflammatory response, balances the effects of insulin in breaking down sugar for energy, and regulates the metabolism of proteins, carbohydrates, and fats.See peer reviewed journal publications: http://www.samaritanpharma.com/publications_and_patents.asp Samaritan Pharmaceuticals: ``Transforming Todays Science Into Tomorrows Cures... Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimers, cancer, heart disease, and infectious disease.It helps maintain blood pressure and cardiovascular function, reduces the immune systems inflammatory response, balances the effects of insulin in breaking down sugar for energy, and regulates the metabolism of proteins, carbohydrates, and fats.About SP-6300:SP-6300 acts by reducing the levels of the rate-limiting enzyme HMGCoA reductase mRNA, leading to reduced activity and decreased cholesterol and corticosteroid biosynthesis.See peer reviewed journal publications: http://www.samaritanpharma.com/publications_and_patents.aspSamaritan Pharmaceuticals: ``Transforming Todays Science Into Tomorrows Cures...Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimers, cancer, heart disease, and infectious disease.In addition, Samaritans sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.Website: http://www.samaritanpharma.com.Please register so we can notify you of upcoming conference calls, news and events.DisclaimerThe company disclaims any information created by an outside party and endorses only information communicated by its press releases, filings, and Website.